Pipeline Overview​

11/14/2024

Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting 

Learn More

​

08/05/2024

Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting

Learn More

​

06/05/2024

Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate

Learn More

​

12/05/2023

Osteal Therapeutics’ VT-X7 Receives FDA’s Breakthrough Therapy Designation for the treatment of periprosthetic joint infection of the hip and knee and completes enrollment of the pivotal APEX-2 trial
Learn More

​

09/28/2023

BioNTX Names Osteal Therapeutics 2023 Rising Star
Learn More

​​

09/21/2023

Osteal Therapeutics Closes $23M Series C Financing
Learn More

​​

02/07/2023

Osteal Therapeutics Announces First Subject Enrollment in Second Phase 2 Clinical Trial of VT-X7 Combination Product for Treatment of Periprosthetic Joint Infection
Learn More

​​

12/29/2022

Osteal Therapeutics Announces Leadership Appointments
Learn More

​​

11/4/22

Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection
Learn More

​​

3/8/22

Osteal Therapeutics Closes an Oversubscribed $30 Million Series B Financing to Advance Platform Therapy for Treatment of Musculoskeletal Infection
Learn More

​​​​